AJANTPHARM.NS Balance Sheet
Ajanta Pharmaceuticals Ltd.
Profit & Loss Balance Sheet Cash Flow
Balance Sheet · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 21:33
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Property, Plant and Equipment | ₹14.08 Bn | ₹13.84 Bn | ₹16.25 Bn | ₹17.26 Bn | PropertyPlantAndEquipment |
| Capital Work-in-Progress | ₹2.09 Bn | ₹2.56 Bn | ₹1.76 Bn | ₹2.58 Bn | CapitalWorkInProgress |
| Goodwill | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | Goodwill |
| Other Intangible Assets | ₹0.89 Bn | ₹0.95 Bn | ₹1.37 Bn | ₹1.41 Bn | OtherIntangibleAssets |
| Non-current Investments | ₹0.25 Bn | ₹0.19 Bn | ₹0.25 Bn | ₹0.28 Bn | NoncurrentInvestments |
| Other Non-current Assets | ₹0.05 Bn | ₹0.09 Bn | ₹0.13 Bn | ₹0.69 Bn | OtherNoncurrentAssets |
| Total Non-current Assets | ₹18.45 Bn | ₹19.07 Bn | ₹21.72 Bn | ₹24.19 Bn | NoncurrentAssets |
| Inventories | ₹8.16 Bn | ₹8.28 Bn | ₹9.04 Bn | ₹9.39 Bn | Inventories |
| Trade Receivables | ₹10.57 Bn | ₹12.47 Bn | ₹11.83 Bn | ₹18.54 Bn | TradeReceivablesCurrent |
| Cash and Cash Equivalents | ₹3.30 Bn | ₹1.29 Bn | ₹1.75 Bn | ₹1.03 Bn | CashAndCashEquivalents |
| Current Investments | ₹5.10 Bn | ₹3.30 Bn | ₹4.39 Bn | ₹5.60 Bn | CurrentInvestments |
| Other Current Assets | ₹0.92 Bn | ₹1.33 Bn | ₹1.23 Bn | ₹2.68 Bn | OtherCurrentAssets |
| Total Current Assets | ₹28.25 Bn | ₹27.22 Bn | ₹28.30 Bn | ₹37.35 Bn | CurrentAssets |
| Total Assets | ₹46.79 Bn | ₹46.38 Bn | ₹50.15 Bn | ₹61.55 Bn | Assets |
| Equity Share Capital | ₹0.25 Bn | ₹0.25 Bn | ₹0.25 Bn | ₹0.25 Bn | EquityShareCapital |
| Other Equity | ₹33.63 Bn | ₹35.42 Bn | ₹37.65 Bn | ₹45.02 Bn | OtherEquity |
| Equity Attributable to Owners | ₹33.88 Bn | ₹35.67 Bn | ₹37.90 Bn | ₹45.27 Bn | EquityAttributableToOwnersOfParent |
| Non-controlling Interests | ₹0.00 Bn | ₹0.00 Bn | N/A | ₹0.00 Bn | NonControllingInterest |
| Total Equity | ₹33.88 Bn | ₹35.67 Bn | ₹37.90 Bn | ₹45.27 Bn | Equity |
| Long-term Borrowings | ₹0.01 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | BorrowingsNoncurrent |
| Total Non-current Liabilities | ₹1.52 Bn | ₹1.75 Bn | ₹2.29 Bn | ₹2.12 Bn | NoncurrentLiabilities |
| Short-term Borrowings | ₹0.00 Bn | ₹0.01 Bn | ₹0.03 Bn | ₹2.12 Bn | BorrowingsCurrent |
| Trade Payables | ₹4.23 Bn | ₹4.63 Bn | ₹4.54 Bn | ₹5.44 Bn | TradePayablesCurrent |
| Other Current Liabilities | ₹0.23 Bn | ₹0.60 Bn | ₹0.91 Bn | ₹1.19 Bn | OtherCurrentLiabilities |
| Total Current Liabilities | ₹11.39 Bn | ₹8.95 Bn | ₹9.96 Bn | ₹14.16 Bn | CurrentLiabilities |
| Total Equity and Liabilities | ₹46.79 Bn | ₹46.38 Bn | ₹50.15 Bn | ₹61.55 Bn | EquityAndLiabilities |
Every figure above is the exact value of the named XBRL element from AJANTPHARM.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).